Posted On: 04/23/2014 7:49:54 AM
Post# of 63648
![Avatar](https://investorshangout.com/images/ProfileImages/934136062_182_A_Dawgg 1 Two 10-baggers at the same time..jpg)
$NEO
[url=First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
edits relating to billing Medicare for FISH testing. ]NeoGenomics[/url] Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
Company Increases Revenue and EPS Guidance for the Full-Year
First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
edits relating to billing Medicare for FISH testing.
[url=First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
![](/m/images/icons/icon_wink.gif)
Company Increases Revenue and EPS Guidance for the Full-Year
First Quarter 2014 Highlights:
Test volume growth of 21%
Revenue growth of 16%
Decline in average cost per test of 7%
Adjusted EBITDA of $1.7 million and net income of $0.1 million
Launch of next generation sequencing profiles for a variety of cancer types
Revenue for the first quarter was $18.2 million, a 16.1% increase over first quarter 2013 revenue on test volume growth of 20.7%. This revenue growth was achieved despite a $700,000 reduction in revenue recorded to account for a conservative interpretation of the unresolved National Correct Coding Initiative ("NCCI"
![](/m/images/icons/icon_wink.gif)
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)